Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk ...

Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular ...

As the Affordable Care Act passed its 15th anniversary this year, Supreme Court Justices continue to deliberate the fate of ...

NYOH joins OneOncology to leverage its patient-first culture and advanced technology solutions, enhancing cancer care delivery and practice growth. The partnership supports NYOH's expansion, including ...

John Michael O'Brien, PharmD, MPH, discussed the changes in managed care over the past 30 years to commemorate the 30th ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't ...

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

Panelists discuss how managing patients with mild cognitive impairment using amyloid-targeting therapies faces significant barriers including limited healthcare infrastructure for complex diagnostic ...

Panelists discuss how newer urinary tract infection (UTI) therapies such as pivmecillinam, sulopenem etzadroxil/probenecid, and gepotidacin demonstrate significantly lower resistance rates (below 5%) ...

Experts discuss how to evaluate the cost-effectiveness of continuous glucose monitoring (CGM) compared to traditional monitoring, considering both clinical and quality outcomes, and what combination ...

Panelists discuss how sulopenem etzadroxil/probenecid, approved in October 2024, functions as an oral β-lactam/β-lactamase inhibitor effective against extended-spectrum β-lactamase producers per SURE ...